Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer’s Disease in the Aging Brain

Brain aging is a multifaceted process that remains poorly understood. Despite significant advances in technology, progress toward identifying reliable risk factors for suboptimal brain health requires realistically complex analytic methods to explain relationships between genetics, biology, and environment. Here we show the utility of a novel unsupervised machine learning technique – Correlation Explanation (CorEx) – to discover how individual measures from structural brain imaging, genetics, plasma, and CSF markers can jointly provide information on risk for Alzheimer’s disease (AD). We examined 829 participants (Mage: 75.3 ± 6.9 years; 350 women and 479 men) from the Alzheimer’s Disease Neuroimaging Initiative database to identify multivariate predictors of cognitive decline and brain atrophy over a 1-year period. Our sample included 231 cognitively normal individuals, 397 with mild cognitive impairment (MCI), and 201 with AD as their baseline diagnosis. Analyses revealed latent factors based on data-driven combinations of plasma markers and brain metrics, that were aligned with established biological pathways in AD. These factors were able to improve disease prediction along the trajectory from normal cognition and MCI to AD, with an area under the receiver operating curve of up to 99%, and prediction accuracy of up to 89.9% on independent “held out” testing data. Further, the most important latent factors that predicted AD consisted of a novel set of variables that are essential for cardiovascular, immune, and bioenergetic functions. Collectively, these results demonstrate the strength of unsupervised network measures in the detection and prediction of AD.

[1]  Kaj Blennow,et al.  Biomarkers in Alzheimer's disease drug development , 2010, Nature Medicine.

[2]  Ralph A. Nixon,et al.  Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.

[3]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[4]  Alex Bateman,et al.  The rise and fall of supervised machine learning techniques , 2011, Bioinform..

[5]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[6]  G. Wagner,et al.  Structural alterations in patients with obsessive–compulsive disorder: a surface-based analysis of cortical volume, surface area and thickness , 2017, Journal of psychiatry & neuroscience : JPN.

[7]  Walter J Koroshetz,et al.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.

[8]  M. Kamal,et al.  Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. , 2016, Current pharmaceutical design.

[9]  A. Fleisher,et al.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. , 2014, The Journal of clinical psychiatry.

[10]  J. Friedman Greedy function approximation: A gradient boosting machine. , 2001 .

[11]  J. Morris,et al.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials , 2017, Alzheimer's & Dementia.

[12]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[13]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[14]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[15]  B. Winblad,et al.  Homocysteine and holotranscobalamin and the risk of Alzheimer disease , 2010, Neurology.

[16]  Isabelle Guyon,et al.  An Introduction to Variable and Feature Selection , 2003, J. Mach. Learn. Res..

[17]  R. Brookmeyer,et al.  National estimates of the prevalence of Alzheimer’s disease in the United States , 2011, Alzheimer's & Dementia.

[18]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[19]  Shirley Pepke,et al.  Comprehensive discovery of subsample gene expression components by information explanation: therapeutic implications in cancer , 2016, BMC Medical Genomics.

[20]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[21]  Guangji Wang,et al.  Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? , 2015, Neuropharmacology.

[22]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[25]  Y. Qian,et al.  Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[27]  Yu-ping Peng,et al.  Th17 Cell-Mediated Neuroinflammation Is Involved in Neurodegeneration of Aβ1-42-Induced Alzheimer’s Disease Model Rats , 2013, PloS one.

[28]  P. Mcgeer,et al.  Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease , 2000, Brain Research.

[29]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[30]  W. Poon,et al.  Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease. , 2017, Neurologic clinics.

[31]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[32]  Simon Lovestone,et al.  Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.

[33]  Michael Weiner,et al.  Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trials , 2013, NeuroImage.

[34]  Yoram Singer,et al.  Using and combining predictors that specialize , 1997, STOC '97.

[35]  L. Tan,et al.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. , 2015, Annals of translational medicine.

[36]  Jakub Szlęk,et al.  Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations , 2015, International journal of nanomedicine.

[37]  D. Catalucci,et al.  Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.

[38]  L. Launer,et al.  Midlife C-reactive protein and risk of cognitive decline: A 31-year follow-up , 2009, Neurobiology of Aging.

[39]  Alzheimer’s Association 2018 Alzheimer's disease facts and figures , 2018, Alzheimer's & Dementia.

[40]  T. Rutherford,et al.  Serum amyloid A , 2010, Cancer.

[41]  D. Frayer SEXUAL DIMORPHISM , 2005 .

[42]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[43]  G. Getz,et al.  The mutual interplay of lipid metabolism and the cells of the immune system in relation to atherosclerosis , 2014, Clinical lipidology.

[44]  P. Kubes,et al.  The neutrophil in vascular inflammation , 2011, Nature Medicine.

[45]  Verónica Bolón-Canedo,et al.  Ensemble feature selection: Homogeneous and heterogeneous approaches , 2017, Knowl. Based Syst..

[46]  Aram Galstyan,et al.  Maximally Informative Hierarchical Representations of High-Dimensional Data , 2014, AISTATS.

[47]  I. T. Ten Berge,et al.  CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.

[48]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[49]  K. Jellinger,et al.  Synaptic Pathology of Alzheimer's Disease a , 1993, Annals of the New York Academy of Sciences.

[50]  A. Batra,et al.  Altered lymphocyte distribution in Alzheimer's disease. , 2007, Journal of psychiatric research.

[51]  Paul M. Thompson,et al.  Age, APOE and sex: Triad of risk of Alzheimer’s disease , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[53]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[54]  M. Naito,et al.  Increased Susceptibility of  Thymocytes to Apoptosis in Mice Lacking AIM, a Novel Murine Macrophage-derived Soluble Factor Belonging to the Scavenger Receptor Cysteine-rich Domain Superfamily , 1999, The Journal of experimental medicine.

[55]  Eric Westman,et al.  Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2012, NeuroImage.

[56]  Gonzalo A. Bello,et al.  Toward Personalized Network Biomarkers in Alzheimer's Disease: Computing Individualized Genomic and Protein Crosstalk Maps , 2017, Front. Aging Neurosci..

[57]  Nathan D. Price,et al.  IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior , 2015, Neuron.

[58]  Greg Ver Steeg,et al.  Unsupervised Learning via Total Correlation Explanation , 2017, IJCAI.

[59]  C. Visser,et al.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.

[60]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[61]  Michael Weiner,et al.  Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features , 2013, NeuroImage.

[62]  H. Vankova Mini Mental State , 2010 .

[63]  P. Tariot,et al.  Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials. , 2015, The journal of prevention of Alzheimer's disease.

[64]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[65]  J. Morris,et al.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement , 2017, Alzheimer's & Dementia.

[66]  I. Melle,et al.  Cortical Volume, Surface Area, and Thickness in Schizophrenia and Bipolar Disorder , 2012, Biological Psychiatry.

[67]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[68]  P. Kubes,et al.  Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.

[69]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[70]  David A. Bell,et al.  A Formalism for Relevance and Its Application in Feature Subset Selection , 2000, Machine Learning.

[71]  L. Westlye,et al.  Differential Longitudinal Changes in Cortical Thickness, Surface Area and Volume across the Adult Life Span: Regions of Accelerating and Decelerating Change , 2014, The Journal of Neuroscience.

[72]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[73]  Reisa A. Sperling,et al.  Preclinical Alzheimer’s Disease , 2014 .

[74]  Norbert Schuff,et al.  Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry , 2011, NeuroImage.

[75]  Lennart Thurfjell,et al.  Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.

[76]  Rena Li,et al.  Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.

[77]  P. Mcgeer,et al.  The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases , 2001, Neurobiology of Aging.

[78]  David A. Bennett,et al.  Sexual dimorphism in predisposition to Alzheimer's disease , 2018, Neurobiology of Aging.

[79]  Aram Galstyan,et al.  Discovering Structure in High-Dimensional Data Through Correlation Explanation , 2014, NIPS.

[80]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[81]  R. Mohs,et al.  The Alzheimer's Disease Assessment Scale , 1996, International Psychogeriatrics.

[82]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[83]  F. Borràs,et al.  The human CD5L/AIM-CD36 axis: A novel autophagy inducer in macrophages that modulates inflammatory responses , 2015, Autophagy.

[84]  Gretel Sanabria-Diaz,et al.  Surface area and cortical thickness descriptors reveal different attributes of the structural human brain networks , 2010, NeuroImage.

[85]  S. Scheff,et al.  Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.

[86]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[87]  C. Mold,et al.  Serum amyloid P component binds to histones and activates the classical complement pathway. , 1992, Journal of immunology.